GW Henssler & Associates Ltd. cut its holdings in Abbott Laboratories (NYSE:ABT) by 96.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 7,240 shares of the healthcare product maker’s stock after selling 182,157 shares during the period. GW Henssler & Associates Ltd.’s holdings in Abbott Laboratories were worth $868,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. boosted its holdings in shares of Abbott Laboratories by 193.5% in the 1st quarter. Meeder Asset Management Inc. now owns 60,216 shares of the healthcare product maker’s stock valued at $7,218,000 after buying an additional 39,698 shares during the period. Regent Peak Wealth Advisors LLC lifted its position in Abbott Laboratories by 284.2% in the 1st quarter. Regent Peak Wealth Advisors LLC now owns 16,933 shares of the healthcare product maker’s stock valued at $2,029,000 after purchasing an additional 12,526 shares during the last quarter. NN Investment Partners Holdings N.V. raised its position in shares of Abbott Laboratories by 0.6% during the 1st quarter. NN Investment Partners Holdings N.V. now owns 418,790 shares of the healthcare product maker’s stock worth $50,189,000 after buying an additional 2,472 shares in the last quarter. JustInvest LLC raised its position in shares of Abbott Laboratories by 74.2% during the 1st quarter. JustInvest LLC now owns 33,569 shares of the healthcare product maker’s stock worth $4,023,000 after buying an additional 14,303 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its position in shares of Abbott Laboratories by 2.9% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 19,552 shares of the healthcare product maker’s stock worth $2,343,000 after buying an additional 548 shares in the last quarter. 72.58% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Randel William Woodgrift sold 1,034 shares of the firm’s stock in a transaction that occurred on Monday, March 1st. The shares were sold at an average price of $120.61, for a total transaction of $124,710.74. Following the completion of the transaction, the senior vice president now directly owns 51,495 shares of the company’s stock, valued at approximately $6,210,811.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrea F. Wainer sold 6,200 shares of the firm’s stock in a transaction on Wednesday, March 3rd. The shares were sold at an average price of $121.79, for a total transaction of $755,098.00. Following the completion of the transaction, the executive vice president now directly owns 51,550 shares of the company’s stock, valued at $6,278,274.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,726 shares of company stock valued at $1,064,230. 1.70% of the stock is owned by company insiders.

Abbott Laboratories stock traded down $2.02 during trading hours on Tuesday, reaching $117.51. 127,109 shares of the company’s stock traded hands, compared to its average volume of 5,216,047. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.19 and a current ratio of 1.70. Abbott Laboratories has a fifty-two week low of $86.16 and a fifty-two week high of $128.54. The firm has a market capitalization of $208.17 billion, a price-to-earnings ratio of 63.24, a PEG ratio of 2.06 and a beta of 0.83. The firm’s 50 day moving average is $120.90 and its 200-day moving average is $115.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Monday, April 19th. The healthcare product maker reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The company had revenue of $10.45 billion for the quarter, compared to the consensus estimate of $10.72 billion. During the same period in the prior year, the company posted $0.65 EPS. The company’s revenue was up 35.2% compared to the same quarter last year. Analysts predict that Abbott Laboratories will post 3.57 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, May 17th. Investors of record on Thursday, April 15th will be given a $0.45 dividend. The ex-dividend date of this dividend is Wednesday, April 14th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.53%. Abbott Laboratories’s dividend payout ratio is 55.56%.

A number of research firms have commented on ABT. Atlantic Securities began coverage on shares of Abbott Laboratories in a research report on Wednesday, April 21st. They set a “neutral” rating and a $122.00 price target on the stock. SVB Leerink boosted their target price on shares of Abbott Laboratories from $115.00 to $128.00 and gave the stock a “market perform” rating in a report on Thursday, January 28th. Morgan Stanley lifted their target price on shares of Abbott Laboratories from $136.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 27th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $128.00 to $137.00 in a research report on Thursday, January 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Abbott Laboratories in a research report on Tuesday, April 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $126.06.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Story: How can investors find ex-dividend dates?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.